# Your page scores 64 out of 100 for sameness against the 3 competitors you named.

Most of what your page says, BD Pyxis™ says too — the overlap is heaviest in the benefits you promise.

- **Your page:** https://intelliguardhealth.com/
- **Compared against:** Bluesight (bluesight.com), Omnicell (omnicell.com), BD Pyxis™ (bd.com)
- **Sameness Index:** 64 — Mostly the same
- **Ownable share:** 25% (of 65% distinctive)
- **Report:** https://grader.wynter.com/c/intelliguardhealth-com-zH8cS78

**How you compare · vs 366 SaaS sites** — 8 points more same than the average SaaS site. The average SaaS site scores 56; you scored 64. You are less same than 95 of the 366 SaaS sites. The best-differentiated site in the set is at 6.
_A single check can move several points between runs; the benchmark averages up to eight sites per category._

> With 3 competitors, commonness can only take 4 distinct values. The figures are honest at that resolution and no finer.

## 1. Sameness Index

| Category | Weight | Score | What it means |
| --- | --- | --- | --- |
| Messaging | 30% | 66 | The most expensive kind of sameness. A buyer cannot tell what job you do that the others do not. |
| Claims | 30% | 100 | Every shared claim is a line already read on another tab. Cut the ones nobody owns and spend the space on something they cannot. |
| Features | 15% | 46 | Expected in a mature category, and the least alarming of the six. Feature parity is normal; leading with it is the mistake. |
| Proof | 10% | 16 | Same kinds of proof as everyone means the proof stops working as proof. It is scored on the kind of evidence, not on which customers are named. |
| Structure | 10% | 39 | The generic SaaS template — hero, logos, three-feature grid, testimonial, CTA. Familiar is not the same as memorable. |
| Visual | 5% | 48 | Weighted lowest on purpose: buyers rarely decide on this. Worth knowing, rarely worth fixing first. |

**Mostly the same** — Most of your claims are also theirs. Only the details differ.

## 2. Closest competitors

| Competitor | Same | Band |
| --- | --- | --- |
| BD Pyxis™ | 77 | Interchangeable |
| Bluesight | 68 | Mostly the same |
| Omnicell | 52 | Half shared |

_Measured from your side: how much of what YOU say each competitor also says, weighted by where you put it._

## 3. Ownable share

**The share of your own page's claim space that is yours to keep.** This is not the inverse of the Sameness Index — it is measured on your claims alone, so the two do not add up to 100 and are not meant to.

25% of your page is unique, relevant and defensible — a strong share, and the thing to protect in any rewrite.

- **Distinctive message share:** 65% — prominent space spent on claims no competitor makes.
- **Ownable share:** 25% — the part of that which is also relevant to how buyers choose and hard to copy.

## 4. Where you sound like everyone else

Most of your set makes each of these and you are spending prominent space on them, ranked by how much. **These are not necessarily lines to delete** — some of what a page has to say is unavoidably shared, and claims about what kind of product you are were left out of this list for exactly that reason. The question each one raises is whether it has earned its space.

- **Real-time item-level inventory visibility and accuracy** (Hero, 100% of the set) — also on Bluesight, Omnicell, BD Pyxis™
  - _"Know Exactly Where Every Critical, High-Value Medication is in Real Time"_
  - Said your way: nobody else makes this exact claim, but everyone occupies the territory.
- **Reduces waste and lowers cost** (Section, 100% of the set) — also on Bluesight, Omnicell, BD Pyxis™
  - _"Better financial control"_
- **Saves staff time through automation** (Section, 100% of the set) — also on Bluesight, Omnicell, BD Pyxis™
  - _"Less manual work, more clinical focus"_
- **Reduces waste and lowers cost** (Section, 100% of the set) — also on Bluesight, Omnicell, BD Pyxis™
  - _"Reduced waste and expiration loss"_
- **Improves compliance, audit readiness and lowers risk** (Section, 100% of the set) — also on Bluesight, Omnicell, BD Pyxis™
  - _"Stronger compliance and audit readiness"_
- **Real-time item-level inventory visibility and accuracy** (Section, 100% of the set) — also on Bluesight, Omnicell, BD Pyxis™
  - _"Real-time accuracy"_
  - Said your way: nobody else makes this exact claim, but everyone occupies the territory.
- **AI and analytics turn data into actionable decisions** (Section, 67% of the set) — also on Bluesight, Omnicell
  - _"Mira Intelligence+ is context-aware software that unifies medication data and delivers predictive insights"_
- **Quantified performance results as proof** (Section, 67% of the set) — also on Bluesight, BD Pyxis™
  - _"99% medication identification accuracy"_
  - Said your way: nobody else makes this exact claim, but everyone occupies the territory.

## 5. Buried gold

Unique, relevant, and sitting in body copy. The cheapest wins here — you already have the differentiation and the page hides it.

- **Transactions traced to provider and patient** (Body, 0% of the set)
  - _"Every transaction tracked to the provider and patient"_
- **Temperature, expiry and recall alerts pushed to users** (Body, 0% of the set)
  - _"Temperature excursion, expiry, and recall alerts pushed to you"_

## 6. Claim inventory

| Claim | Type | Placement | Common | Sayability | Relevant | Ownership |
| --- | --- | --- | --- | --- | --- | --- |
| Real-time item-level visibility of every dose | outcome | Hero | 0% | some | yes | Unique and owned |
| A single unified platform, not point components | category | Hero | 0% | anyone | yes | Unique for now |
| RFID-based medication inventory tracking | category | Hero | 33% | some | yes | Contested |
| Only/first connected RFID ecosystem in category | category | Hero | 0% | structural | no | Unique and owned |
| Better financial control and cost savings | outcome | Section | 67% | anyone | yes | Commodity |
| Less manual work frees staff for clinical care | outcome | Section | 67% | anyone | yes | Commodity |
| Reduce medication waste and expiration loss | outcome | Section | 67% | anyone | yes | Commodity |
| Stronger compliance and audit readiness | outcome | Section | 67% | anyone | yes | Commodity |
| Real-time data accuracy | quality | Section | 0% | anyone | yes | Unique for now |
| Software unifies data and gives predictive insights | capability | Section | 67% | anyone | yes | Commodity |
| Quantified medication identification/inventory accuracy rates | proof | Section | 0% | some | yes | Unique and owned |
| Enterprise-wide control across all facilities | capability | Section | 33% | anyone | yes | Contested |
| Fast secure OR medication access without workflow disruption | outcome | Section | 0% | some | yes | Unique and owned |
| Holds RFID patents | proof | Section | 0% | structural | no | Unique and owned |
| Hospitals manage enormous medication counts across sites | proof | Section | 0% | anyone | no | Unique for now |
| Legacy systems built for volume, not precision | capability | Section | 0% | anyone | no | Unique for now |
| Modular plug-and-play expansion across settings | capability | Section | 0% | some | yes | Unique and owned |
| Instant self-serve savings estimate in 60 seconds | outcome | Section | 0% | anyone | no | Unique for now |
| Large installed base of hospital customers | proof | Section | 0% | some | yes | Unique and owned |
| Volume of medications tracked to date | proof | Section | 0% | some | no | Unique and owned |
| Chain of custody helps prevent diversion | capability | Body | 33% | some | yes | Contested |
| Reduce on-hand inventory and surface savings | outcome | Body | 33% | anyone | yes | Contested |
| Transactions traced to provider and patient | capability | Body | 0% | some | yes | Unique and owned |
| Single view integrating RFID, EHR, cabinets, other systems | capability | Body | 67% | some | yes | Commodity |
| Utilization data supports charge capture and 340B | outcome | Body | 33% | some | yes | Contested |
| Role-based prioritized actions rather than dashboards | capability | Body | 0% | anyone | no | Unique for now |
| Case-level accountability across clinical roles | capability | Body | 0% | some | no | Unique and owned |
| Models multi-year savings across waste, charge capture, 340B | capability | Body | 0% | some | no | Unique and owned |
| Temperature, expiry and recall alerts pushed to users | capability | Body | 0% | some | yes | Unique and owned |

## What we compared

- **Intelliguard** (your page) — https://intelliguardhealth.com/
- **Bluesight** — https://bluesight.com/
- **Omnicell** — https://www.omnicell.com/
- **BD Pyxis™** — https://www.bd.com/en-us/products-and-solutions/products/product-brands/pyxis

## What this does and does not tell you

An AI read each page and wrote down the claims it makes, then grouped the claims that say the same thing. **No score in this report was written by a model** — every number is computed from those groupings in our own code, with the weights shown above.

## The only way to know if it matters

This report can tell you where your messaging overlaps. It cannot tell you whether a buyer would care, or which of your reasons to buy actually land. Put the page in front of real B2B buyers in your target market and ask them.

[Test it with real buyers](https://wynter.com)